Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.

Prostate cancer and prostatic diseases - 1 Dec 2010

Dahlman A, Edsjö A, Halldén C, Persson J L, Fine S W, Lilja H, Gerald W, Bjartell A

Abstract excerpt

We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on β-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenetic silencing. Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Gene Expression Regulation, Neoplastic

Share to Microarray Analysis

Share to Prostatic Neoplasms

Share to Salivary Proteins and Peptides

Share to Seminal Plasma Proteins

Source

Identifiers

PMID: 20680031
DOI: 10.1038/pcan.2010.25

Genes

MSMB
CRISP3
KLK3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.PMID 20680031Read ↗

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Semantic proximity Read ↗

The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.Semantic proximity Read ↗

Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosisSemantic proximity Read ↗

Validation of prostate cancer risk variants by CRISPR/Cas9 mediated genome editingSemantic proximity Read ↗

CRISP3 expression drives prostate cancer invasion and progression.Semantic proximity Read ↗

Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.Semantic proximity Read ↗

Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer.Semantic proximity Read ↗

The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.Semantic proximity Read ↗

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancerSemantic proximity Read ↗

Pro-survival factor EDEM3 confers therapy resistance in prostate cancerSemantic proximity Read ↗

Deregulated expression of selected histone methylases and demethylases in prostate carcinomaSemantic proximity Read ↗

Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.